Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders.
As part of the National Institute of Mental Health Strategic Plan for Mood Disorders Research effort, the Clinical Trials and Translation Workgroup was asked to define priorities for clinical trials in mood disorders and for research on how best to translate the results of such research to clinical practice settings. Through two face-to-face meetings and a series of conference calls, we established priorities based on the literature to date and what was known about research currently in progress in this area. We defined five areas of priority that cut across developmental stages, while noting that research on adult mood disorders was at a more advanced stage in each of these areas than research on child or geriatric disorders. The five areas of priority are: 1) maximizing the effectiveness and cost-effectiveness of initial (acute) treatments for mood disorders already known to be efficacious in selected populations and settings when they are applied across all populations and care settings; 2) learning what further treatments or services are most likely to reduce symptoms and improve functioning when the first treatment is delivered well, but the mood disorder does not remit or show adequate improvement; 3) learning what treatments or services are most cost-effective in preventing recurrence or relapse and maintaining optimal functioning after a patient's mood disorder has remitted or responded maximally to treatment; 4) developing and validating clinical, psychosocial, biological, or other markers that predict: a) which treatments are most effective, b) course of illness, c) risk of adverse events/tolerability and acceptability for individual patients or well-defined subgroups of patients; 5) developing clinical trial designs and methods that result in lower research costs and greater generalizability earlier in the treatment development and testing process. A rationale for the importance of each of these priorities is provided.
D000368:Aged; D015415:Biomarkers / Q000032:analysis; D001714:Bipolar Disorder / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000592:standards*; D003362:Cost-Benefit Analysis; D019052:Depression, Postpartum / Q000188:drug therapy; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D019964:Mood Disorders / Q000175:diagnosis* / Q000191:economics / Q000628:therapy*; D009315:National Institute of Mental Health (U.S.); D017410:Practice Guidelines as Topic; D011247:Pregnancy; D011293:Premenstrual Syndrome / Q000628:therapy; D012106:Research / Q000592:standards* / Q000639:trends*; D016896:Treatment Outcome; D014481:United States; D000092864:Suicide Prevention
D015415:Biomarkers